MOSCOW, 1 Jul — RIA Novosti. Drug “Aviewer” for the treatment of patients COVID-19 has already been tested on more than 180 patients, said the Deputy Director of the National research center of tuberculosis and infectious diseases, Ministry of health Vladimir closets.
He noted that testing of “Avifauna” continues: if the first stage was the selection of an optimal dosage of the drug, the second goal was to evaluate the efficacy and safety of medicines.
“the Study is expected to be very large, more than 300 patients, to be more precise, 330 patients should be included in the study,” added closets. According to him, during the tests, the effectiveness of the Russian drug was about 90%.
“the Most important and well-known undesirable phenomenon is its possible teratogenic effect, i.e. the effect on the fetus, so very strict rules introduced to control the safety of this drug, it is a mandatory testing for the presence of pregnancy before taking the drug and the need to control possible pregnancy while taking the drug,” — he stressed.
the First preparation of direct antiviral action of “Aviewer” production RDIF and Chemrar that violate the mechanisms of propagation of the coronavirus SARS-CoV-2, last week received the approval of the Ministry of health.
After that, Russia can start to put the “Avidavit” abroad. As the head of the Russian direct investment Fund (RDIF) Kirill Dmitriev, the applications it has received from countries in the Middle East and Latin America.
According to the latest data, in Russia since the beginning of the epidemic revealed more than 414 thousand infected with coronavirus, of which 4855 died, over 175 thousand were cured. Earlier Vladimir Putin said that the peak of the spread of coronavirus in Russia, according to scientists, is passed.
the Country began gradually to remove a ban, however, in some regions, including in Moscow, the regime of self-isolation extended. The mayor of Moscow Sergey Sobyanin noted that some of the restrictive measures in the city can be saved before the advent of vaccines against SARS-CoV-2.
